One-year soy isoflavone supplementation prevents early postmenopausal bone loss but without a dose-dependent effect

Hui Ying Huang, Hsiao Ping Yang, Hui Ting Yang, Tung Chuan Yang, Ming-Che Hsieh, Shih Yi Huang

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

It is believed that soy isoflavone has much potential effectiveness on the postmenopausal status; however, the optimal dose for preventing postmenopausal bone loss still remains unclear. This open-labeled, self-controlled pilot study was undertaken to determine the effect of 1-year supplementation of different high dosages of soy isoflavone in postmenopausal Taiwanese women. Forty-three women aged 45-67 years were enrolled and randomly assigned into a control (C), 100 mg/day isoflavone (IF100) and 200 mg/day isoflavone (IF200) groups for 1 year. Dual-energy X-ray absorptiometry and other related biochemical markers of bone metabolism were measured. Results indicated that the decrease in bone mineral density (BMD) was significant for lumbar vertebrae L1-3, L1-4 and the femur neck in the C group; surprisingly, the BMD of L1-3 was significantly elevated in the IF100 group; however, there were no consistent responses in the IF200 group. No significant change except loss of the bone mineral content of Ward's triangle (P=.003) was found in the IF200 group after treatment. The percentage change at L1-3 was less (P=.04) in the IF200 group when compared to the IF100 group. A relatively uniform direction of bone formation in expanding the weight and area with different rates of change resulted in different BMD changes. Both indicated a change of bone formation patterns with the higher-dose supplement. A protective effect of IF100 on estrogen-related bone loss was observed. A lack of a benefit such as high safety in the IF200 group for 1-year administration was ensured and lacked undesirable side effects.

Original languageEnglish
Pages (from-to)509-517
Number of pages9
JournalJournal of Nutritional Biochemistry
Volume17
Issue number8
DOIs
Publication statusPublished - Aug 2006

Fingerprint

Postmenopausal Osteoporosis
Isoflavones
Bone Density
Bone
Osteogenesis
Minerals
Bone and Bones
Lumbar Vertebrae
Femur Neck
Photon Absorptiometry
Estrogens
Biomarkers
Safety
Weights and Measures
Metabolism
X rays
Therapeutics

Keywords

  • Bone mineral content (BMC)
  • Bone mineral density (BMD)
  • Postmenopausal women
  • Soy isoflavone

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

One-year soy isoflavone supplementation prevents early postmenopausal bone loss but without a dose-dependent effect. / Huang, Hui Ying; Yang, Hsiao Ping; Yang, Hui Ting; Yang, Tung Chuan; Hsieh, Ming-Che; Huang, Shih Yi.

In: Journal of Nutritional Biochemistry, Vol. 17, No. 8, 08.2006, p. 509-517.

Research output: Contribution to journalArticle

@article{98cf19e8b43241f7959fe3f8699a28bb,
title = "One-year soy isoflavone supplementation prevents early postmenopausal bone loss but without a dose-dependent effect",
abstract = "It is believed that soy isoflavone has much potential effectiveness on the postmenopausal status; however, the optimal dose for preventing postmenopausal bone loss still remains unclear. This open-labeled, self-controlled pilot study was undertaken to determine the effect of 1-year supplementation of different high dosages of soy isoflavone in postmenopausal Taiwanese women. Forty-three women aged 45-67 years were enrolled and randomly assigned into a control (C), 100 mg/day isoflavone (IF100) and 200 mg/day isoflavone (IF200) groups for 1 year. Dual-energy X-ray absorptiometry and other related biochemical markers of bone metabolism were measured. Results indicated that the decrease in bone mineral density (BMD) was significant for lumbar vertebrae L1-3, L1-4 and the femur neck in the C group; surprisingly, the BMD of L1-3 was significantly elevated in the IF100 group; however, there were no consistent responses in the IF200 group. No significant change except loss of the bone mineral content of Ward's triangle (P=.003) was found in the IF200 group after treatment. The percentage change at L1-3 was less (P=.04) in the IF200 group when compared to the IF100 group. A relatively uniform direction of bone formation in expanding the weight and area with different rates of change resulted in different BMD changes. Both indicated a change of bone formation patterns with the higher-dose supplement. A protective effect of IF100 on estrogen-related bone loss was observed. A lack of a benefit such as high safety in the IF200 group for 1-year administration was ensured and lacked undesirable side effects.",
keywords = "Bone mineral content (BMC), Bone mineral density (BMD), Postmenopausal women, Soy isoflavone",
author = "Huang, {Hui Ying} and Yang, {Hsiao Ping} and Yang, {Hui Ting} and Yang, {Tung Chuan} and Ming-Che Hsieh and Huang, {Shih Yi}",
year = "2006",
month = "8",
doi = "10.1016/j.jnutbio.2006.01.003",
language = "English",
volume = "17",
pages = "509--517",
journal = "Journal of Nutritional Biochemistry",
issn = "0955-2863",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - One-year soy isoflavone supplementation prevents early postmenopausal bone loss but without a dose-dependent effect

AU - Huang, Hui Ying

AU - Yang, Hsiao Ping

AU - Yang, Hui Ting

AU - Yang, Tung Chuan

AU - Hsieh, Ming-Che

AU - Huang, Shih Yi

PY - 2006/8

Y1 - 2006/8

N2 - It is believed that soy isoflavone has much potential effectiveness on the postmenopausal status; however, the optimal dose for preventing postmenopausal bone loss still remains unclear. This open-labeled, self-controlled pilot study was undertaken to determine the effect of 1-year supplementation of different high dosages of soy isoflavone in postmenopausal Taiwanese women. Forty-three women aged 45-67 years were enrolled and randomly assigned into a control (C), 100 mg/day isoflavone (IF100) and 200 mg/day isoflavone (IF200) groups for 1 year. Dual-energy X-ray absorptiometry and other related biochemical markers of bone metabolism were measured. Results indicated that the decrease in bone mineral density (BMD) was significant for lumbar vertebrae L1-3, L1-4 and the femur neck in the C group; surprisingly, the BMD of L1-3 was significantly elevated in the IF100 group; however, there were no consistent responses in the IF200 group. No significant change except loss of the bone mineral content of Ward's triangle (P=.003) was found in the IF200 group after treatment. The percentage change at L1-3 was less (P=.04) in the IF200 group when compared to the IF100 group. A relatively uniform direction of bone formation in expanding the weight and area with different rates of change resulted in different BMD changes. Both indicated a change of bone formation patterns with the higher-dose supplement. A protective effect of IF100 on estrogen-related bone loss was observed. A lack of a benefit such as high safety in the IF200 group for 1-year administration was ensured and lacked undesirable side effects.

AB - It is believed that soy isoflavone has much potential effectiveness on the postmenopausal status; however, the optimal dose for preventing postmenopausal bone loss still remains unclear. This open-labeled, self-controlled pilot study was undertaken to determine the effect of 1-year supplementation of different high dosages of soy isoflavone in postmenopausal Taiwanese women. Forty-three women aged 45-67 years were enrolled and randomly assigned into a control (C), 100 mg/day isoflavone (IF100) and 200 mg/day isoflavone (IF200) groups for 1 year. Dual-energy X-ray absorptiometry and other related biochemical markers of bone metabolism were measured. Results indicated that the decrease in bone mineral density (BMD) was significant for lumbar vertebrae L1-3, L1-4 and the femur neck in the C group; surprisingly, the BMD of L1-3 was significantly elevated in the IF100 group; however, there were no consistent responses in the IF200 group. No significant change except loss of the bone mineral content of Ward's triangle (P=.003) was found in the IF200 group after treatment. The percentage change at L1-3 was less (P=.04) in the IF200 group when compared to the IF100 group. A relatively uniform direction of bone formation in expanding the weight and area with different rates of change resulted in different BMD changes. Both indicated a change of bone formation patterns with the higher-dose supplement. A protective effect of IF100 on estrogen-related bone loss was observed. A lack of a benefit such as high safety in the IF200 group for 1-year administration was ensured and lacked undesirable side effects.

KW - Bone mineral content (BMC)

KW - Bone mineral density (BMD)

KW - Postmenopausal women

KW - Soy isoflavone

UR - http://www.scopus.com/inward/record.url?scp=33746021317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746021317&partnerID=8YFLogxK

U2 - 10.1016/j.jnutbio.2006.01.003

DO - 10.1016/j.jnutbio.2006.01.003

M3 - Article

C2 - 16563719

AN - SCOPUS:33746021317

VL - 17

SP - 509

EP - 517

JO - Journal of Nutritional Biochemistry

JF - Journal of Nutritional Biochemistry

SN - 0955-2863

IS - 8

ER -